What’s In A Datapalooza? Reply


“What’s in a name?

That which we call a rose

By any other name would smell as sweet.”

Shakespeare aside, as Lilly COI gets close to attending our first “Datapalooza” – in this case The Health Datapolooza sponsored by the U.S Department of Health and Human Services – I find myself wondering what exactly a Datapalooza is, what we might expect, what we might contribute and what we might gain.  We’re absolute newbies, and look forward to learning from those with experience. More…

Contesting TB 2

A quick nod to the Stop TB Partnership and it’s New Drug Working Group, who have put together the Innovate TB (inTB) Contest.  inTB gathers videos, photos and write-ups that tell stories of innovation focused on the fight against TB.

Here’s our TB Commons entry along with a few others that have caught my eye:

TB Commons

TB Commons is our notion of a disease commons, where those interested in advancing clinical research on TB can access clinicaltrials.gov data using our Clinical Collection tool.  In addition, a powerful Answers Forum serves as a place to share collections of trials, and generate knowledge related to TB research.  Give it a try!

The Delft Youth Theatre for Health Group

The Delft Youth Theatre for Health Group raises awareness through performances of “Bad News? Good News!” in an Afrikan community.  No lights, camera, props or trained actors needed – just everyday people learning about and sharing valuable information to fight disease, and having some fun doing it. More…

Meet Dave Crumbacher 4

David Crumbacher is the Tech Lead for the Lilly Clinical Open Innovation Team, giving direction and guidance to a group of developers that, in his words, are “gifted, unique, and highly valued.”  Dave’s history at Eli Lilly and Company on the forefront of transformational technology is deep.  Dave joined Lilly after graduating from Southern Illinois University with a degree in computer science.  His contributions at Lilly have helped drug developers leverage leading technologies to innovate in the fight against disease.

Dave brings more than 20 years of experience in high performance computing and networking to Lilly Clinical Open Innovation.  From clustered VAX environments to today’s Internet-enabled cloud computing, Dave’s career has focused on helping scientists take advantage of computational and networking power.  He has a unique capacity for translation that few people have; he has a gift to share the  most complex technology with those who need to apply it.  It is a gift he attributes to patient coaching from his earliest days at Lilly.  But it may go further back than that.

You have a unique ability to describe the most technical aspects of your work for people.  Where did you get that?

I grew up in a small mid-western town where my dad ran a TV repair shop.  In those days, TV technology was a mystery to a lot of people, but my father was the kind of man who took the time to explain to his customers what was going on with their set, and what he could do to fix it for them.  I think that his ability to do that must have rubbed off on me at an early age.

Spreading The Word Or Preaching To The Choir? 5

The following blog post is by Mark Delong.

Mark DeLong leads the information technology group at Duke University’s Institute for Genome Sciences & Policy. He is particularly interested in harmonizing life sciences research processes with information technology and in emerging computation technologies including specialized computer processors, “cloud” computing, high performance computing, and development of high-throughput analysis systems. He and his group strongly advocate use of open source and open data. He studied philosophy as an undergraduate, and earned his PhD from Duke in English medieval and Renaissance literature and culture.

The opinions expressed by Mark are his own, and do not necessarily reflect those of the Lilly COI Team.


On Saturday evening after the third Sage Congress broke up, I wandered down to the Hyatt’s restaurant to mix with other stragglers and relax a bit. I met Jerry Matczak and Tom Krohn from Lilly Clinical Open Innovation, who had the same thing in mind.

“What did you think?” Tom asked, prodding me for a judgment of the event.

I had been wondering exactly what I thought ever since we wrapped things up that afternoon, and I paused and said, “I think it felt a little like a revival.”